We are live on ! Find out more
SCMP

Sucampo Pharmaceuticals, Inc.
SCMP

Delisted

SCMP was delisted on the 12th of February, 2018.

167 hedge funds and large institutions have $272M invested in Sucampo Pharmaceuticals, Inc. in 2017 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 68 increasing their positions, 46 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

170% more call options, than puts

Call options by funds: $1.97M | Put options by funds: $730K

48% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 46

0% more funds holding

Funds holding: 167167 (0)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 23

5% less capital invested

Capital invested by funds: $287M → $272M (-$14.9M)

Holders
167
Holders Change
Holders Change %
0%
% of All Funds
4.16%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
23
Increased
68
Reduced
46
Closed
23
Calls
$1.97M
Puts
$730K
Net Calls
+$1.24M
Net Calls Change
+$883K
Name Holding Trade Value Shares
Change
Change in
Stake
AllianceBernstein
76
AllianceBernstein
Tennessee
$403K +$91.7K +9,000 +31%
Two Sigma Advisers
77
Two Sigma Advisers
New York
$392K -$87.7K -8,600 -19%
Canada Life
78
Canada Life
Manitoba, Canada
$374K
MIM
79
Monashee Investment Management
Massachusetts
$368K +$357K +35,000 New
New York State Common Retirement Fund
80
New York State Common Retirement Fund
New York
$367K -$620K -60,805 -63%
SM
81
Sabby Management
Florida
$349K -$528K -51,800 -61%
FIM
82
Freedom Investment Management
Connecticut
$332K -$205K -20,156 -39%
PCM
83
Palisade Capital Management
New Jersey
$315K
Connor, Clark & Lunn Investment Management (CC&L)
84
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$287K -$6.12K -600 -2%
EMG
85
Ellington Management Group
Connecticut
$286K +$151K +14,800 +119%
Comerica Bank
86
Comerica Bank
Texas
$284K -$14.5K -1,418 -5%
ProShare Advisors
87
ProShare Advisors
Maryland
$277K -$14K -1,378 -5%
UBS Group
88
UBS Group
Switzerland
$276K -$45.3K -4,445 -14%
BNP Paribas Financial Markets
89
BNP Paribas Financial Markets
France
$266K +$174K +17,078 +208%
Squarepoint
90
Squarepoint
New York
$260K -$64.8K -6,360 -20%
State of Tennessee, Department of Treasury
91
State of Tennessee, Department of Treasury
Tennessee
$246K
KBC Group
92
KBC Group
Belgium
$238K +$231K +22,692 New
AIA
93
Affinity Investment Advisors
California
$233K -$90.3K -8,856 -29%
First Trust Advisors
94
First Trust Advisors
Illinois
$210K -$4.58K -449 -2%
Manulife (Manufacturers Life Insurance)
95
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$209K +$8.05K +790 +4%
O
96
OppenheimerFunds
New York
$202K +$28.8K +2,821 +17%
State of Wisconsin Investment Board
97
State of Wisconsin Investment Board
Wisconsin
$199K +$194K +19,000 New
TPSF
98
Texas Permanent School Fund
Texas
$192K +$4.06K +398 +2%
AIG
99
American International Group
New York
$191K +$38.7K +3,795 +26%
MLICM
100
Metropolitan Life Insurance Company (MetLife)
New York
$185K

SCMP Hedge Fund Activity: Q2 2017 in Review

167 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Sucampo Pharmaceuticals, Inc. (SCMP) for Q2 2017, worth a combined $272M — down 5.2% from $287M a quarter earlier.

Fund positioning in SCMP was balanced in Q2 2017: 23 funds opened new positions, 23 closed out, 68 added to existing stakes and 46 trimmed.

The largest buyer was NEA Management Company, opening a new position worth an estimated $12.8M. The largest seller was Redwood Investments, exiting entirely with an estimated $6.63M sold.

  • 167 institutional investors held Sucampo Pharmaceuticals, Inc. (SCMP) as of Q2 2017, unchanged from Q1 2017.
  • Funds reported $272M of Sucampo Pharmaceuticals, Inc. stock for Q2 2017, down 5.2% quarter-over-quarter.
  • 23 funds opened new Sucampo Pharmaceuticals, Inc. positions in Q2 2017 and 23 closed out, a net change of 0 holders.
  • The largest Sucampo Pharmaceuticals, Inc. buyer in Q2 2017 was NEA Management Company, an estimated $12.8M added.
  • The largest Sucampo Pharmaceuticals, Inc. seller in Q2 2017 was Redwood Investments, an estimated $6.63M sold.

Based on aggregated 13F filings for Q2 2017.